Disfungsi Seksual Non-Organik

01Pathophysiology

Sexual function follows a predictable physiological cycle originally described by Masters and Johnson and later refined by Kaplan into a three-phase model: desire, arousal, and orgasm. Each phase is governed by a distinct neurohormonal pathway, and dysfunction can occur at any point along this sequence.

Desire is primarily regulated by the limbic system, with testosterone (in both men and women) and dopaminergic pathways serving as the main neurochemical drivers. Psychogenic loss of desire occurs when higher cortical inhibition overrides limbic drive. This is commonly seen in patients with chronic stress, depression, or relational dissatisfaction, where the prefrontal cortex effectively "vetoes" sexual motivation before the arousal cascade even begins.

Arousal depends on the parasympathetic nervous system. In men, parasympathetic outflow via the pelvic splanchnic nerves (S2-S4) triggers nitric oxide release in the corpus cavernosum, leading to smooth muscle relaxation and penile engorgement. In women, the same parasympathetic mechanism governs clitoral engorgement and vaginal lubrication through transudation. Performance anxiety is the classic psychogenic disruptor here: anxiety activates the sympathetic nervous system, which directly antagonizes parasympathetic-mediated vasodilation. The patient wants to perform but the catecholamine surge prevents the physiological response from occurring, creating a vicious cycle of failure and escalating anxiety.

Orgasm is a spinal reflex arc modulated by supraspinal centers. The sympathetic nervous system mediates emission (in men), while somatic motor neurons via the pudendal nerve mediate the rhythmic contractions of orgasm. Psychogenic orgasmic dysfunction typically involves excessive cognitive monitoring during intercourse, a phenomenon sometimes called "spectatoring," where the patient mentally observes and evaluates their own performance rather than allowing reflexive progression to climax.

Vaginismus has a distinct pathophysiology: it is a conditioned fear response. Prior painful experiences (or anticipation of pain based on cultural messaging or trauma) trigger involuntary contraction of the pubococcygeus and surrounding pelvic floor muscles. This is a reflex mediated through the somatic motor system, not a voluntary contraction, which is why patients cannot simply "relax" on command.

Premature ejaculation in its psychogenic form is thought to involve low serotonergic tone in the central ejaculatory pathways. Serotonin (5-HT) normally acts as a brake on ejaculation at the level of the spinal ejaculatory generator. Anxiety and sympathetic hyperactivation further lower the ejaculatory threshold.

A critical concept for exam purposes: PPDGJ-III requires that the dysfunction is not entirely attributable to an organic disorder, substance use, or another psychiatric condition. If a patient's sexual dysfunction is secondary to, for example, a depressive episode, the primary diagnosis is the depression, not the sexual dysfunction.

02Classification and Clinical Manifestation

03Diagnostic Workup

The workup for non-organic sexual dysfunction is fundamentally a diagnosis of exclusion. The clinician must systematically rule out organic, pharmacological, and psychiatric causes before concluding that the dysfunction is psychogenic.

Step 1: Take a thorough sexual history. This is the most powerful diagnostic tool available. The history should establish when the dysfunction began, whether it is present in all situations or only with certain partners or contexts, and what psychosocial circumstances surrounded its onset. Situational dysfunction (e.g., erectile failure only with a partner but not during masturbation, or vaginismus only with penetration attempts but not during gynecological examination under anesthesia) strongly points toward a psychogenic origin.

Step 2: Screen for psychiatric comorbidity. Depression is the most common psychiatric cause of decreased libido and anorgasmia. Anxiety disorders commonly underlie performance-related erectile dysfunction and premature ejaculation. PTSD, particularly from sexual trauma, is a frequent driver of sexual aversion and vaginismus. If a full psychiatric syndrome is present, the sexual dysfunction is typically classified under that primary diagnosis.

Step 3: Review medications. SSRIs, beta-blockers, antipsychotics, spironolactone, and opioids are all well-known causes of iatrogenic sexual dysfunction. A temporal correlation between medication initiation and symptom onset suggests a pharmacological rather than psychogenic cause.

Step 4: Obtain targeted laboratory studies only when the history suggests a possible organic contribution. A young patient with acute-onset, situational erectile dysfunction following a breakup does not need a hormonal panel. A middle-aged patient with gradually progressive, generalized loss of desire and erectile failure warrants testosterone, prolactin, thyroid function, and glucose testing.

Step 5: NPT testing is reserved for cases where the distinction between psychogenic and organic erectile dysfunction remains unclear after history and labs. The presence of normal nocturnal erections is the strongest single piece of evidence favoring a psychogenic etiology.

04Management & Treatment

The cornerstone of treatment for all subtypes is psychotherapy, not pharmacotherapy. This is a high-yield testing point: the first-line intervention is always some form of psychological or behavioral treatment.

Sensate Focus Therapy (Masters & Johnson) deserves special attention because it is the most frequently tested behavioral intervention. The treatment proceeds in stages. In Stage 1, the couple engages in non-genital touching only, with intercourse explicitly prohibited. The goal is to remove performance pressure and re-establish physical intimacy without demand. In Stage 2, genital touching is introduced but intercourse remains off-limits. In Stage 3, intercourse is gradually reintroduced. Each stage typically lasts one to two weeks. The prohibition on intercourse during early stages is itself therapeutic because it breaks the anxiety-performance failure cycle.

For premature ejaculation, the squeeze technique involves the partner applying firm pressure to the frenulum of the glans when the patient signals approaching ejaculation. This is held for 10-20 seconds until the urge subsides, then stimulation resumes. The stop-start method follows the same principle but without manual compression. Both techniques train the patient to recognize and tolerate pre-orgasmic arousal levels. Pharmacologically, dapoxetine is the only SSRI specifically approved for on-demand use in premature ejaculation in many countries. Its short half-life (1.5 hours) makes it suitable for as-needed dosing. Daily SSRIs (paroxetine, sertraline) are alternatives that work by tonically raising serotonergic inhibition of the ejaculatory reflex, but they take 1-2 weeks to reach full effect.

For vaginismus, the graded dilator protocol is the most evidence-supported intervention. Treatment starts with the smallest dilator, which the patient inserts herself in a private, controlled setting. Progression to the next size occurs only when the current size can be inserted comfortably. The entire course typically takes 4-8 weeks. Importantly, the patient must control the process at all times. Forcing progression or having the partner control insertion is counterproductive and can worsen the conditioned fear response.

Contraindications and cautions:

• PDE-5 inhibitors are contraindicated in patients taking nitrates (risk of severe hypotension).

• Anti-androgens carry significant side effects including hepatotoxicity, depression, and osteoporosis with long-term use.

• Benzodiazepines for sexual aversion must be short-term only due to dependence risk and the fact that they can impair arousal themselves.

05Differential Diagnosis & Distractors

06Traps & High-Yield Pearls

The most common way students lose points on questions about non-organic sexual dysfunction is by failing to recognize the hierarchy of diagnoses. PPDGJ-III is explicit: if the sexual dysfunction is secondary to another psychiatric condition (depression, mania, anxiety disorder) or to a medical condition or medication, you do not diagnose it as a primary sexual dysfunction. The vignette will often include subtle clues pointing to an underlying mood disorder or medication side effect, and the student who reflexively picks "sexual dysfunction" as the answer without considering these upstream causes will select the wrong diagnosis.

A second common trap involves confusing the subtypes. The distinction between "lack of desire" and "sexual aversion" is subtle but testable. Both patients avoid sex, but the patient with aversion experiences an active negative emotional reaction (disgust, fear, anxiety), while the patient with low desire is simply indifferent. Similarly, "lack of sexual enjoyment" is distinct from "orgasmic dysfunction" because in the former, the patient can achieve orgasm but derives no pleasure from it, while in the latter, orgasm itself is absent or delayed.

The third trap is the situational vs. generalized distinction. Exam vignettes will often embed a detail indicating that the patient functions normally in one context (masturbation, different partner, nocturnal erections) but not another. This is the single most reliable indicator that the etiology is psychogenic. Students who skip past this detail and focus on the dysfunction itself will be led toward organic diagnoses and unnecessary workup.

Finally, remember that the first step in management is always non-pharmacological. A common distractor answer is to jump to PDE-5 inhibitors for psychogenic erectile dysfunction or SSRIs for premature ejaculation. While these medications have a role, the tested "best initial step" for psychogenic sexual dysfunction is psychoeducation, behavioral therapy, or couples therapy. Medications are adjuncts, not replacements for addressing the underlying psychological mechanism.